Skip to main content

Table 2 Patients and sequential change of max SUVmax

From: The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy

Pt. #

Age

Treatment

MSKCC classification

max SUVmax before treatment

max SUVmax at nadir

max SUVmax at PD

PFS (month)

Number of PET/CT evaluation

1

70′s

sorefanib

favorable

8.1

4.8

9.5

15.0

7

2

60′s

sorefanib

intermediate

8.2

8.0

8.0

3.2

3

3

50′s

sunitnib

intermediate

3.9

not decrease

4.0

4.1

3

4

50′s

sunitnib

intermediate

9.1

0.0

6.2

26.1

13

5

70′s

sorefanib

intermediate

5.3

2.7

4.6

21.0

9

6

60′s

sorefanib

intermediate

7.2

5.5

6.3

5.5

4

7

30′s

sunitnib

favorable

16.1

10.4

15.0

7.8

6

8

60′s

sunitnib

poor

14.3

12.2

12.2

0.9

2

9

80′s

sunitnib

intermediate

5.1

not decrease

6.4

2.2

2

10

50′s

sunitnib

intermediate

5.8

4.2

6.8

7.4

4

11

60′s

sunitnib

intermediate

8.2

3.4

7.0

6.1

4

12

70′s

sorefanib

intermediate

2.3

not decrease

4.4

3.6

3

13

80′s

sorefanib

intermediate

6.9

0.0

7.6

18.5

7

14

50′s

sunitnib

favorable

5.2

3.6

5.1

19.4

5

15

50′s

sunitnib

favorable

12.5

4.5

7.8

4.8

3

16

60′s

sorefanib

favorable

5.2

4.8

7.1

26.2

9

17

70′s

sorefanib

intermediate

6.5

5.2

5.7

6.5

3

18

60′s

sorefanib

favorable

4.1

3.6

4.6

6.9

4

19

50′s

sorefanib

favorable

5.8

4.5

7.8

22.3

7

20

70′s

sunitnib

intermediate

9.1

3.6

8.1

17.4

7

21

50′s

sorefanib

poor

9.5

not decrease

12.0

1.4

2

22

60′s

sorefanib

intermediate

7.4

not decrease

8.8

3.6

3

23

50′s

sunitnib

intermediate

8.2

5.5

5.5

0.9

2

24

70′s

sorefanib

intermediate

9.4

7.5

8.5

6.2

4

25

70′s

sorefanib

intermediate

7.0

5.9

7.6

4.2

3

26

60′s

sunitnib

poor

8.2

6.4

6.6

3.4

3

27

60′s

sorefanib

intermediate

5.2

not decrease

6.5

7.0

4

28

70′s

sunitnib

intermediate

8.4

6.2

7.2

10.7

5

29

50′s

sunitnib

poor

9.1

9.0

9.0

0.9

2

30

60′s

sorefanib

favorable

5.6

4.0

4.8

6.9

4

31

50′s

sunitnib

intermediate

11.0

not decrease

12.8

1.5

2

32

70′s

sunitnib

intermediate

6.4

4.2

7.0

6.5

4

33

60′s

sunitnib

intermediate

10.6

10.3

10.3

1.0

2

34

60′s

sorefanib

intermediate

5.5

not decrease

6.0

4.7

3

35

60′s

sorefanib

intermediate

10.1

not decrease

13.3

0.9

2

36

60′s

sunitnib

intermediate

3.7

not decrease

4.8

9.9

5

37

70′s

sorefanib

favorable

3.9

2.2

4.6

6.5

3

38

60′s

sunitnib

intermediate

7.9

5.2

6.7

2.9

4